Analysts at Credit Suisse hoisted their price objective on shares of Boston Scientific Corp. (NYSE:BSX) from $10.50 to $11.00 in a research report issued to clients and investors on Friday, AnalystRatingsNetwork reports. Credit Suisse’s price target suggests a potential upside of 0.36% from the stock’s previous close.
Shares of Boston Scientific Corp. (NYSE: BSX) traded down 0.18% during mid-day trading on Friday, hitting $10.94. Boston Scientific Corp. has a 52 week low of $5.04 and a 52 week high of $11.11. The stock’s 50-day moving average is currently $9.4. The company’s market cap is $14.652 billion.
Boston Scientific Corp. (NYSE:BSX) last released its earnings data on Thursday, July 25th. The company reported $0.18 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.08. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.78 billion. During the same quarter in the prior year, the company posted $0.17 earnings per share. The company’s quarterly revenue was down 1.0% on a year-over-year basis. On average, analysts predict that Boston Scientific Corp. will post $0.42 earnings per share for the current fiscal year.
BSX has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Boston Scientific Corp. from $8.50 to $9.80 in a research note to investors on Friday. They now have a “market perform” rating on the stock. Separately, analysts at Barclays Capital raised their price target on shares of Boston Scientific Corp. from $9.00 to $12.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Boston Scientific Corp. from $11.00 to $13.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Fifteen analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $9.44.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.